Abstract
Although obstructive sleep apnea (OSA) has been clinically reported to be associated with acute coronary syndrome (ACS), the pathogenesis between the two is unclear. Herein, we analyzed and screened out the prospective molecular marker. To explore the candidate genes, as well as signaling cascades involved in ACS related to OSA, we extracted the integrated differentially expressed genes (DEGs) from the intersection of genes from the Gene Expression Omnibus (GEO) cohorts and text mining, followed by enrichment of the matching cell signal cascade through DAVID analysis. Moreover, the MCODE of Cytoscape software was employed to uncover the protein–protein interaction (PPI) network and the matching hub gene. A total of 17 and 56 integrated human DEGs in unstable angina (UA) and myocardial infarction (MI) group associated with OSAs that met the criteria of |log2 fold change (FC)|≥ 1, adjusted P < 0.05, respectively, were uncovered. After PPI network construction, the top five hub genes associated with UA were extracted, including APP, MAPK3, MMP9, CD40 and CD40LG, whereas those associated with MI were PPARG, MAPK1, MMP9, AGT, and TGFB1. The establishment of the aforementioned candidate key genes, as well as the enriched signaling cascades, provides promising molecular marker for OSA-related ACS, which will to provide a certain predictive value for the occurrence of ACS in OSA patients in the future.
Similar content being viewed by others
Introduction
Obstructive sleep apnea (OSA) represents a severely underdiagnosed (~ 80%) form of sleep-disordered breathing1,2,3,4,5,6. Obstructive sleep apnea (OSA) is highly prevalent in patients with cardiovascular diseases7,8. Increasing evidence indicates that OSA is associated with incidence and progression of coronary artery disease9,10,11 and cerebrovascular disease12. Compared with the general population, prevalence of OSA is higher in acute coronary syndrome (ACS) patients and ranges from 36 to 63% across various ethnicities13. Notably, among patients with coronary artery disease, those with ACS represent a high-risk subset and generally have higher mortality than patients with stable angina14. In addition, observational studies have examined whether OSA significantly increased the risk of recurrent cardiovascular events in patients with ACS and/or undergoing percutaneous coronary intervention (PCI)15,16,17,18. Despite the huge advancements in ACS research, the prognosis of ACS treatment is still poor. With the onset age of ACS patients gradually getting younger, it is imperative to establish the etiology, as well as the molecular features, of ACS disease. Therefore, we explore the molecular biomarkers by studying the correlation between OSA and ACS disease to provide evidence for early diagnosis, prevention, and treatment of this disease.
At present, high-throughput sequencing techniques such as molecular diagnosis, prognosis estimation, as well as drug target discovery (which can be employed to assess the gene expression differences, as well as the variable splicing variation), are gradually considered to have important clinical significance in disease research. The Integrated Gene Expression Database (GEO), a publicly available website supported by the National Center for Biotechnology Information (NCBI), harbors dozens of basic experimental disease gene expression patterns and is extensively employed to explore key genes and prospective mechanisms of disease onset and development19. Though the pathogenesis of OSA has been found to be related to ACS recently, its pathogenesis, as well as the molecular mechanism remain unknown. Hence, we need to utilize the gene expression chip in the bulletin database and analyze its data through modern software to find new diagnostic markers and therapeutic targets20.
In this study, we retrieved human unstable angina (UA) and myocardial infarction (MI) gene expression patterns GSE60993 and GSE24519 from the GEO website. After that, the R software (version 3.6.3) was used to screen for differentially expressed genes (DEG)21,22. Then, the genes related to obstructive sleep apnea were obtained by text mining. We use the online tool Venny to analyze the intersection of DEG and text mining gene sets to obtain common genes, and we further used different bioinformatics methods to perform gene ontology, signal pathway enrichment annotations, protein and protein interactions for these common genes the study. In this article, we have studied candidate genes and signal pathways involved in ACS related to OSA, which will help provide a certain predictive value for the occurrence of ACS in OSA patients in the future.
Methods
Data abstraction
We abstracted the gene expression chip data GSE60993 and GSE24519 from the NCBI Gene Expression Comprehensive (GEO) web resource (https://www.ncbi.nlm.nih.gov/geo/)19,23. The GSE60993 cohort contains seven normal control and nine UA samples, while the GSE24519 dataset includes four normal control and four MI samples.
Identification of DEGs
The core R package was used to process the downloaded matrix files. After normalization, the differences between UA or MI and the control group were determined by truncation criteria |log2 fold change (FC)|≥ 1, adjusted P < 0.05), and we selected the remarkable DEGs for downstream analyses24. In order to further investigate DEGs, we selected 10 up-regulated and 10 down-regulated mRNAs with the most fold change as the candidate DEGs for subsequent studies (Table 1).
Text mining
We carried out the text mining based on the pubmed2ensembl public tool (http://pubmed2ensembl.ls.manchester.ac.uk/). When manipulated, pubmed2ensembl retrieves all the gene names found in the existing literature relevant to the search topic. We searched for the concept of “obstructive sleep apnea”. We then screened all the genes associated with the topic from the results. Finally, we used the gene set obtained by text mining and the previously obtained differential gene set for the next step of analysis after the intersection.
Gene ontology analysis of DEGs and KEGG pathway analysis
The obtained DEGs were imported to David V. 6.8 (https://david.ncifcrf.gov/). The GO annotation and KEGG pathway enrichment were carried out using the web resource25,26,27, which provided a sequence of functional annotation tools for systematic analysis of biological significance of gene lists. The above gene tables were analyzed with P < 0.05 as the significant threshold.
Assessment of the PPI network of the DEGs
We used the STRING online search tool to analyze the protein–protein interaction (PPI) data encoded by DEG28, and only the combination score > 0.6 was considered significant. Then, the PPI network was analyzed and visualized by using Cytoscape, and the first five hub genes were determined as per the connectivity between DEGs. The standard default setting of the MCODE parameter. The function enrichment of DEGs of each module was analyzed, with P < 0.05 as the cutoff standard.
Diagnostic analysis of DEGs and prognosis.
In order to further analyze whether the differentially expressed target mRNA related to prognosis has diagnostic value, subject receiver operating characteristic curve (ROC) analysis uses the open-source network tool Hiplot (https://hiplot.com.cn/basic).
Results
DEGs identification
Firstly, 587 DEGs were selected from UA samples and normal controls in the GSE60993 data set through limma package screening of R software. Of these, 299 upregulated genes and 288 downregulated genes were selected. At the same time, 2916 differentially expressed genes, including 1647 upregulated genes and 1269 downregulated genes, were obtained by analyzing the MI samples in the GSE24519 data set and the normal control group. Then, the overall distribution of the two data sets and the first 100 DEGs are represented by volcano map and heatmap, respectively (Fig. 1A–D). Figure 1E,F, respectively, show the correlation between the top 5 differential genes in UA and MI in each sample. Sample using |log2 fold change (FC)|≥ 1 criteria and adjusted P < 0.05.
Through text mining, 339 human genes associated with OSA were selected. After the DEGs in the microarray data were crossed, the intersection of selected genes was obtained, and 17 genes involved in UA group and 56 genes involved in MI group were obtained (Fig. 2A,B).
Function and signal pathway enrichment analysis
After introducing the DEGs obtained above into DAVID, we subjected them to GO and KEGG enrichment analysis to study the biological functions of DEGs integrated in UA and MI associated with chronic periodontitis. In the GO analysis results, 27 biological process terms (BP), 15 cell component terms (CC), and 8 molecular function terms (MF) were uncovered in the DEGs integrated by UA. P < 0.05 signified threshold significance. Overall, 6 genes were primarily abundant in BP term to “inflammatory response”, 11 genes were located in the “plasma membrane” of CC term, and 15 genes were abundant in the MF term “protein binding” as indicated in Fig. 3A. For MI, integrated DEGs were remarkably abundant in 139 GO terms consisting of 103 BP terms, 18 CC terms and 18 MF terms. Besides, the genes were abundant in the following terms: modulation of positive regulation of gene expression in BP and extracellular space in CC, as well as protein binding in MF, which constituted the top 3 GO annotation terms in which the integrated genes were most remarkably enriched (Fig. 4A).
The KEGG enrichment assessment demonstrated that the integrated DEGs were remarkably enriched in the KEGG cascade Toxoplasmosis, Asthma and Primary immunodeficiency in UA group (Fig. 3B) and Proteoglycans in cancer, Cytokine-cytokine receptor interaction and FoxO signaling pathway in the MI group (Fig. 4B).
Module screening from the PPI network
Based on the 17 UA group genes and the 56 MI group genes, the Cytoscape publicly available platform and the STRING resource were employed to develop the PPI network, perform module analysis, and visualization. Consequently, we developed a PPI network bearing 24 crosstalk based on 15 integrated DEGs related to UA (Fig. 5). Moreover, we developed a PPI network in the MI group containing 38 integrated DEGs (Fig. 6A). Based on the degree value, the top five hub genes extracted from the UA group consisted of APP (amyloid beta precursor protein), MAPK3 (mitogen-activated protein kinase 3), MMP9 (matrix metallopeptidase 9), CD40 (CD40 molecule) and CD40LG (CD40 ligand). On the other hand, in the MI group, the top five hub genes were PPARG (peroxisome proliferator activated receptor gamma), MAPK1 (mitogen-activated protein kinase 1), MMP9 (matrix metallopeptidase 9), AGT (angiotensinogen), and TGFB1 (transforming growth factor beta 1) (Table 2).
We employed the MCODE algorithm to determine highly interconnected subnets, which are frequently protein complexes, as well as components of cascades, as per the topological structure. However, we found that there is no highly clustered mou module in UA by calculation. So, we selected the two most important modules from MI group for further analysis (Fig. 6B,C). Additional functional enrichment assessment of the established modules demonstrated that genes in the MI module were abundant in the GO terms of “glucose homeostasis”, “caveola”, “enzyme binding”, and the KEGG cascade of “FoxO signaling pathway” (Table 3).
Diagnosis prediction of DEGs related to prognosis.
We used the ROC curve to research the prediction effects of APP, MAPK3, MMP9, CD40 and CD40LG in UA, and PPARG, MAPK1, MMP9, AGT and TGFB1 in MI (Fig. 7). Interestingly, the AUC values of the above-mentioned differentially expressed target mRNAs are all > 0.7. This result suggests that for OSA patients, the above genes have potential diagnostic value for UA and MI.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Consent for publication
All authors consent to the publication of this study.
Discussion
In a multicenter international study, OSA was shown to independently predict adverse cardiovascular events. Therefore, a new potential treatment method for preventing the progression of ACS has emerged: active treatment OSA. However, at present, the pathogenesis and effective treatment of OSA for ACS remain unclear. Hence, it is imperative to explore the molecular mechanism of the ACS after OCS to determine efficient biomarkers and effective approaches for the diagnosis, monitoring, and treatment of patients. In previous reports, new genetic variations and associated quantitative traits associated with OSA susceptibility have been identified at the genome-wide significance level. In previous reports, new genetic variations and associated quantitative traits associated with OSA susceptibility have been identified at the genome-wide significance level29. Meanwhile, Farias et al. recently have discovered that that allele rs12415421 was an important predictor of the incidence of OSA30.
Herein, 17 genes in UA and 56 genes in MI linked to OSA were uncovered for functional analysis using the GO, and the KEGG enrichment assessments. Additionally, the PPARG gene comprised one of the hub genes uncovered by the PPI network. PPARG can adjust the balance between glucose and fatty acid oxidation, which plays an important role in the reconstruction of human myocardial infarction after ischemia31,32,33. Moreover, previous evidence has suggested that PPARG may be a risk factor for cardiovascular diseases such as metabolic syndrome, obesity, diabetes and hypertension34,35,36,37. PPARG is a member of the nuclear hormone receptor superfamily, which can the recruit the transcriptional coactivators necessary to initiate the transcription of target genes and may also play a protective role in the development of MI in many studies38,39,39. At the same time, previous studies have also found that PPARG may play an important role in the pathophysiological mechanism of OSA40,41, and qPCR detection suggests that the expression of PPARG in OSA patients is significantly different from that in the control group42.
The functional enrichment analysis of the highly connected module showed that the genes in the MI module were mainly enriched in the KEGG term FoxO signaling pathway. FoxOs participate in a variety of cell functions including apoptosis, cell differentiation, desoxyribonucleic acid injury and repair43,44. FoxOs are key signal proteins within the signal transduction of growth factors and are also regulated by the ubiquitin proteasome pathway. In previous studies, the FoxO regulatory pathway had been triggered by the PI3K/AKT pathway, which mediates the function of cell proliferation and growth45. So far, the correlation between FoxO signaling pathway and OSA and ACS has not been reported in the previous literature.
The cleaved product of the glycoprotein amyloid precursor protein (APP) is Aβ, which aggregates into Aβ plaques. According to the amyloid cascade hypothesis, it is these plaques that are responsible for AD pathology46. Soluble Aβ species can bind to and produce toxicity to various neuronal receptors, leading to cellular oxidative stress and epigenetic-mediated transcription disorders47. However, recent studies have shown that soluble Aβ has beneficial physiological effects on certain functions, such as regulating cellular signaling pathways and synaptic function48. The main driving force of the pathological progression of AD is the accumulation of Aβ in the brain, which leads to synaptic loss and neuronal cell death49,50,51. In addition, some evidence has been found that the continuous accumulation of cerebrovascular Aβ plays a role in cerebral microhemorrhage 52,53 and vascular cognitive impairment54.
CD40 is a costimulatory molecule in the constitutive expression of B lymphocytes and is expressed in a variety of cells, such as endothelial cells (ECs), monocytes, macrophages and smooth muscle cells (SMCs)55. In Antoniades et al. 's study, CD40 was found to be involved in the immune pathogenesis of ACS 56 due to its bi-cellular activation through the signaling pathways C-Jun, NF-κB and ERK 1/2, resulting in the secretion of inflammatory cytokines, adhesion molecules, and platelet activation55. However, soluble forms of CD40 and CD40L were significantly associated with adverse cardiovascular events in patients with ACS57,58, suggesting that they are potential targets for therapeutic agents 56. A recent study found that the soluble CD40 ligand (sCD40L) level of OSA patients is significantly increased, and it can be improved by continuous positive airway pressure therapy59. This means that OSA seems to have a clear correlation with the pre-atherosclerotic state, and this state can be continuously monitored by measuring the level of sCD40L.
MMP9 has been shown in many studies to be significantly associated with cardiovascular disease. Moreover, it was also confirmed in our results that MMP9 was highly expressed in both datasets. MMP9 is a protease of the MMP family that is capable of degrading a broad spectrum of extracellular matrix components and is held responsible for vascular remodeling and breakdown of the fibrous cap of atherosclerotic lesions leading to plaque vulnerability60. MMPs are a family of zinc-dependent proteinases capable of degrading various structural components of ECM, thus leading to ECM destruction and plaque rupture61. At the same time, MMP9 has been found in a number of autoimmune diseases and biological processes, such as pulmonary inflammation, hemorrhage, infection and cancer62,63. Therefore, we believe that MMP9 may have a certain relationship with OSA.
MAPK1 is mostly concentrated in the cytoplasm, and activated MAPK1 translocates to the nucleus and activates the expression of target genes in tumor tissues64. Many previous studies have demonstrated that MAPK1 plays an important role in atherosclerotic lesions or processes65,66,67. Furthermore, MAPK1 were both up-regulated in coronary heart disease (CAD)68. At the same time, MAPK pathway also plays a role in stroke progression69,70.
In addition to the genes described above that are known to be associated with OSA and ACS, we also found four potential targeted genes that have not been clearly reported in the literature.
MAPK3, referred to as the mitogen-activated protein kinase 3, is a MAP kinase family member and participates in an extensive array of biological processes, including cell proliferation, as well as angiogenesis. MAPK3 may serve as the intrafollicular mediator that triggers the expansion of the cumulus cell-oocyte complex (COC), as well as the maturation of the oocytes71,72,73. The extracellular, as well as intracellular, mitogenic stimuli activate the MAPK3 cascade, which has pivotal functions in cellular differentiation, proliferation and survival74. The study of colorectal cancer by Schmitz et al. showed that the expression of MAPK3 is related to poor prognosis75.
Angiotensin (AGT), a plasma globulin of the silk fibroin family, is converted to angiotensin I by renin. Angiotensin converting enzyme (ACE) cleaves angiotensin I and converts to angiotensin II. Angiotensin II then causes increased arterial pressure by participating in intravascular fluid volume elevation and vasoconstriction. Finally, angiotensin II functions through angiotensin receptor type 1 (AGTR1) and angiotensin receptor type 2 (AGTR2)76,77,78,79.
According to previous reports80,81,82,83,84,85, TGFβ1 is secreted by a variety of cells, such as peripheral blood monocytes, macrophages, platelets, vascular smooth muscle cells (VSMCs), and renal cells. Its regulatory function on the vessel wall is directed at VSMC, endothelial cells and extracellular matrix. Although there is a significant correlation between TGFβ1 and the pathogenesis of atherosclerosis, the relationship between plasma TGFβ1 levels and the risk of ACS remains unclear81,86,87,88. This is because the exact mechanism of TGFβ1 signaling in the vascular system is still not fully understood82,83,85,89.
The CD40L gene consists of five exons and four introns. Studies have shown that if CD40L expression is low or it is not expressed, impaired immunoglobulin class-switching while mice overexpressing CD40L have chronic inflammation90. Notably, dinucleotide microsatellite with cytosine-adenine (CA) repeats in the CD40LG 3-untranslated region (3-UTR) described as highly polymorphisms have been found to be associated with multiple diseases, such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)91,92,93.
Conclusions
By employing a sequence of bioinformatics tools for gene expression profiling, we established the core function of candidate key genes, and the enriched signaling cascades constituting the “FoxO signaling pathway” in the molecular modulation network of ACS via integrated bioinformatic analysis. This provides a possible target for the prediction and clinical treatment of ACS in OSA patients in the future. However, in vitro, as well as in vivo studies, should be conducted to verify our findings.
Data availability
All data is available under reasonable request.
References
Punjabi, N. M. et al. Sleep-disordered breathing and mortality: A prospective cohort study. PLoS Med. 6, e1000132. https://doi.org/10.1371/journal.pmed.1000132 (2009).
Gottlieb, D. J. et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: The sleep heart health study. Circulation 122, 352–360. https://doi.org/10.1161/CIRCULATIONAHA.109.901801 (2010).
Punjabi, N. M. The epidemiology of adult obstructive sleep apnea. Proc. Am. Thorac. Soc. 5, 136–143. https://doi.org/10.1513/pats.200709-155MG (2008).
Young, T., Evans, L., Finn, L. & Palta, M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 20, 705–706. https://doi.org/10.1093/sleep/20.9.705 (1997).
Young, T. et al. Sleep disordered breathing and mortality: Eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 31, 1071–1078 (2008).
Young, T. et al. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 328, 1230–1235. https://doi.org/10.1056/nejm199304293281704 (1993).
Javaheri, S. et al. Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences. J. Am. Coll. Cardiol. 69, 841–858. https://doi.org/10.1016/j.jacc.2016.11.069 (2017).
Drager, L. F. et al. Sleep apnea and cardiovascular disease: Lessons from recent trials and need for team science. Circulation 136, 1840–1850. https://doi.org/10.1161/CIRCULATIONAHA.117.029400 (2017).
Arzt, M., Hetzenecker, A., Steiner, S. & Buchner, S. Sleep-disordered breathing and coronary artery disease. Can. J. Cardiol. 31, 909–917. https://doi.org/10.1016/j.cjca.2015.03.032 (2015).
Weinreich, G. et al. Association of obstructive sleep apnoea with subclinical coronary atherosclerosis. Atherosclerosis 231, 191–197. https://doi.org/10.1016/j.atherosclerosis.2013.09.011 (2013).
Tan, A. et al. OSA and coronary plaque characteristics. Chest 145, 322–330. https://doi.org/10.1378/chest.13-1163 (2014).
Martinez-Garcia, M. A. et al. Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: Effect of CPAP treatment. Eur. Respir. J. 39, 906–912. https://doi.org/10.1183/09031936.00011311 (2012).
Koo, C. Y. et al. Effects of ethnicity on the prevalence of obstructive sleep apnoea in patients with acute coronary syndrome: A pooled analysis of the ISAACC trial and sleep and stent study. Heart Lung Circ. 26, 486–494. https://doi.org/10.1016/j.hlc.2016.09.010 (2017).
Giustino, G. et al. Impact of clinical presentation (stable angina pectoris vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on long-term outcomes in women undergoing percutaneous coronary intervention with drug-eluting stents. Am. J. Cardiol. 116, 845–852. https://doi.org/10.1016/j.amjcard.2015.06.010 (2015).
Mazaki, T. et al. Impact of sleep-disordered breathing on long-term outcomes in patients with acute coronary syndrome who have undergone primary percutaneous coronary intervention. J. Am. Heart Assoc. 5. https://doi.org/10.1161/jaha.116.003270 (2016).
Yumino, D., Tsurumi, Y., Takagi, A., Suzuki, K. & Kasanuki, H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am. J. Cardiol. 99, 26–30. https://doi.org/10.1016/j.amjcard.2006.07.055 (2007).
Meng, S. et al. Impact of obstructive sleep apnoea on clinical characteristics and outcomes in patients with acute coronary syndrome following percutaneous coronary intervention. J. Int. Med. Res. 37, 1343–1353. https://doi.org/10.1177/147323000903700509 (2009).
Lee, C. H. et al. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation 133, 2008–2017. https://doi.org/10.1161/CIRCULATIONAHA.115.019392 (2016).
Barrett, T. et al. NCBI GEO: Archive for functional genomics data sets–update. Nucleic Acids Res. 41, D991-995. https://doi.org/10.1093/nar/gks1193 (2013).
Guo, Y., Bao, Y., Ma, M. & Yang, W. Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int. J. Mol. Sci. 18. https://doi.org/10.3390/ijms18040722 (2017).
Racine, J. S. RStudio: A platform-independent IDE for R and Sweave. J. Appl. Economet. 27, 167–172. https://doi.org/10.1002/jae.1278 (2012).
Smyth, G. K. in Bioinformatics and Computational Biology Solution Using R and Bioconductor Statistics for Biology and Health (eds R. Gentalman et al.) 397–420 (2005).
Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210. https://doi.org/10.1093/nar/30.1.207 (2002).
Reiner, A., Yekutieli, D. & Benjamini, Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19, 368–375. https://doi.org/10.1093/bioinformatics/btf877 (2003).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545–D551. https://doi.org/10.1093/nar/gkaa970 (2021).
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951. https://doi.org/10.1002/pro.3715 (2019).
Franceschini, A. et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808–D815. https://doi.org/10.1093/nar/gks1094 (2013).
Cade, B. E. et al. Genetic associations with obstructive sleep apnea traits in hispanic/latino Americans. Am. J. Respir. Crit. Care Med. 194, 886–897. https://doi.org/10.1164/rccm.201512-2431OC (2016).
Farias Tempaku, P. et al. Genome-wide association study reveals two novel risk alleles for incident obstructive sleep apnea in the EPISONO cohort. Sleep Med. 66, 24–32. https://doi.org/10.1016/j.sleep.2019.08.003 (2020).
Liao, H. H., Jia, X. H., Liu, H. J., Yang, Z. & Tang, Q. Z. The role of PPARs in pathological cardiac hypertrophy and heart failure. Curr. Pharm. Des. 23, 1677–1686. https://doi.org/10.2174/1381612822666160928150040 (2017).
Finck, B. N. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc. Res. 73, 269–277. https://doi.org/10.1016/j.cardiores.2006.08.023 (2007).
Zhang, Y. F. et al. Crosstalk between microRNAs and peroxisome proliferator-activated receptors and their emerging regulatory roles in cardiovascular pathophysiology. Ppar Res. 2018. https://doi.org/10.1155/2018/8530371 (2018).
Wang, L. P. et al. Association between PPAR gamma 2 Pro12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China. Genet. Mol. Res. 11, 2929–2938. https://doi.org/10.4238/2012.May.18.13 (2012).
Ho, J. S. et al. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res. Clin. Pract. 97, 483–491. https://doi.org/10.1016/j.diabres.2012.03.012 (2012).
Yilmaz-Aydogan, H. et al. Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol. Cell. Biochem. 358, 355–363. https://doi.org/10.1007/s11010-011-0987-y (2011).
Niu, X. et al. Weighted gene co-expression network analysis identifies critical genes in the development of heart failure after acute myocardial infarction. Front. Genet. 10, 1214. https://doi.org/10.3389/fgene.2019.01214 (2019).
Legchenko, E. et al. PPAR gamma agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci.Transl. Med. 10. https://doi.org/10.1126/scitranslmed.aao0303 (2018).
Cao, R., Dong, Y. & Kural, K. C. Integrating literature-based knowledge database and expression data to explore molecular pathways connecting PPARG and myocardial infarction. PPAR Res. 2020, 1892375. https://doi.org/10.1155/2020/1892375 (2020).
Lehrke, M. & Lazar, M. A. The many faces of PPARgamma. Cell 123, 993–999. https://doi.org/10.1016/j.cell.2005.11.026 (2005).
Janani, C. & Ranjitha Kumari, B. D. PPAR gamma gene—A review. Diabetes Metab. Syndr.9, 46–50. https://doi.org/10.1016/j.dsx.2014.09.015 (2015).
Gharib, S. A., Hayes, A. L., Rosen, M. J. & Patel, S. R. A pathway-based analysis on the effects of obstructive sleep apnea in modulating visceral fat transcriptome. Sleep 36, 23–30. https://doi.org/10.5665/sleep.2294 (2013).
Vurusaner, B., Poli, G. & Basaga, H. Tumor suppressor genes and ROS: Complex networks of interactions. Free Radic. Biol. Med. 52, 7–18. https://doi.org/10.1016/j.freeradbiomed.2011.09.035 (2012).
Gomes, A. R., Brosens, J. J. & Lam, E. W. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 7, 3133–3136. https://doi.org/10.4161/cc.7.20.6920 (2008).
Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K. & Fukamizu, A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 100, 11285–11290. https://doi.org/10.1073/pnas.1934283100 (2003).
Karisetty, B. C. et al. Amyloid-beta peptide impact on synaptic function and neuroepigenetic gene control reveal new therapeutic strategies for Alzheimer’s disease. Front. Mol. Neurosci. 13, 577622. https://doi.org/10.3389/fnmol.2020.577622 (2020).
Chen, G. F. et al. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 38, 1205–1235. https://doi.org/10.1038/aps.2017.28 (2017).
Brothers, H. M., Gosztyla, M. L. & Robinson, S. R. The physiological roles of amyloid-beta peptide hint at new ways to treat Alzheimer's disease. Front. Aging Neurosci. 10. https://doi.org/10.3389/fnagi.2018.00118 (2018).
Tanzi, R. E. The synaptic A beta hypothesis of Alzheimer disease. Nat. Neurosci. 8, 977–979. https://doi.org/10.1038/nn0805-977 (2005).
Selkoe, D. J. Alzheimer’s disease is a synaptic failure. Science 298, 789–791. https://doi.org/10.1126/science.1074069 (2002).
Hardy, J. & Selkoe, D. J. Medicine - The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297, 353–356. https://doi.org/10.1126/science.1072994 (2002).
Greenberg, S. M. et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann. Neurol. 64, 587–591. https://doi.org/10.1002/ana.21528 (2008).
Dierksen, G. A. et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann. Neurol. 68, 545–548. https://doi.org/10.1002/ana.22099 (2010).
Vermeer, S. E. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215–1222. https://doi.org/10.1056/NEJMoa022066 (2003).
Michel, N. A., Zirlik, A. & Wolf, D. CD40L and its receptors in atherothrombosis-An update. Front. Cardiovasc. Med. 4, 40. https://doi.org/10.3389/fcvm.2017.00040 (2017).
Antoniades, C., Bakogiannis, C., Tousoulis, D., Antonopoulos, A. S. & Stefanadis, C. The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J. Am. Coll. Cardiol. 54, 669–677. https://doi.org/10.1016/j.jacc.2009.03.076 (2009).
Varo, N. et al. Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 108, 1049–1052. https://doi.org/10.1161/01.CIR.0000088521.04017.13 (2003).
Rondina, M. T. et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 109, 196–201. https://doi.org/10.1159/000106683 (2008).
Kobayashi, K. et al. Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 129, 632–637. https://doi.org/10.1378/chest.129.3.632 (2006).
Galis, Z. S. & Khatri, J. J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90, 251–262 (2002).
Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-18. https://doi.org/10.1016/j.jacc.2005.10.065 (2006).
McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206. https://doi.org/10.1126/science.289.5482.1202 (2000).
Dufour, A. & Overall, C. M. Missing the target: Matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34, 233–242. https://doi.org/10.1016/j.tips.2013.02.004 (2013).
Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83. https://doi.org/10.1128/mmbr.00031-10 (2011).
Bujold, K. et al. CD36-mediated cholesterol efflux is associated with PPAR gamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc. Res. 83, 457–464. https://doi.org/10.1093/cvr/cvp118 (2009).
Banfi, C. et al. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro. J. Thromb. Haemost. 9, 1608–1619. https://doi.org/10.1111/j.1538-7836.2011.04366.x (2011).
Chen, Y. L. et al. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 35, 948–959. https://doi.org/10.1161/atvbaha.114.305116 (2015).
Zhu, Y., Yang, T. R., Duan, J. L., Mu, N. H. & Zhang, T. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging-Us 11, 1089–1109. https://doi.org/10.18632/aging.101766 (2019).
Sawe, N., Steinberg, G. & Zhao, H. Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J. Neurosci. Res. 86, 1659–1669. https://doi.org/10.1002/jnr.21604 (2008).
Clancy, P., Koblar, S. A. & Golledge, J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis 236, 108–115. https://doi.org/10.1016/j.atherosclerosis.2014.06.011 (2014).
Park, J. Y. et al. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 303, 682–684. https://doi.org/10.1126/science.1092463 (2004).
Shimada, M., Hernandez-Gonzalez, I., Gonzalez-Robayna, I. & Richards, J. S. Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: Key roles for prostaglandin synthase 2 and progesterone receptor. Mol. Endocrinol. 20, 1352–1365. https://doi.org/10.1210/me.2005-0504 (2006).
Hsieh, M. et al. Luteinizing hormone-dependent activation of the epidermal growth factor network is essential for ovulation. Mol. Cell. Biol. 27, 1914–1924. https://doi.org/10.1128/mcb.01919-06 (2007).
Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295–308. https://doi.org/10.1038/nrc2109 (2007).
Schmitz, K. J. et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch. 450, 151–159. https://doi.org/10.1007/s00428-006-0342-y (2007).
Brand, E. et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur. J. Hum. Genet. 10, 715–723. https://doi.org/10.1038/sj.ejhg.5200874 (2002).
George, A. J., Thomas, W. G. & Hannan, R. D. The renin-angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer 10, 745–759. https://doi.org/10.1038/nrc2945 (2010).
Yin, G., Yan, C. & Berk, B. C. Angiotensin II signaling pathways mediated by tyrosine kinases. Int. J. Biochem. Cell Biol. 35, 780–783. https://doi.org/10.1016/s1357-2725(02)00300-x (2003).
Sobczuk, P., Szczylik, C., Porta, C. & Czarnecka, A. M. Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol. Lett. 14, 5059–5068. https://doi.org/10.3892/ol.2017.6826 (2017).
Nikol, S. et al. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J. Clin. Invest. 90, 1582–1592. https://doi.org/10.1172/JCI116027 (1992).
Frutkin, A. D. et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 29, 1251–1257. https://doi.org/10.1161/ATVBAHA.109.186593 (2009).
Schulick, A. H. et al. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc. Natl. Acad. Sci. U S A 95, 6983–6988. https://doi.org/10.1073/pnas.95.12.6983 (1998).
Suthanthiran, M. et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. U S A 97, 3479–3484. https://doi.org/10.1073/pnas.050420897 (2000).
Majesky, M. W., Lindner, V., Twardzik, D. R., Schwartz, S. M. & Reidy, M. A. Production of transforming growth factor beta 1 during repair of arterial injury. J. Clin. Invest. 88, 904–910. https://doi.org/10.1172/JCI115393 (1991).
Khan, R., Agrotis, A. & Bobik, A. Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc. Res. 74, 223–234. https://doi.org/10.1016/j.cardiores.2007.02.012 (2007).
Najar, R. A., Ghaderian, S. M. H. & Panah, A. S. T. Association of transforming growth factor-beta 1 gene polymorphisms with genetic susceptibility to acute myocardial infarction. Am. J. Med. Sci. 342, 365–370. https://doi.org/10.1097/MAJ.0b013e318215908a (2011).
Chen, Y., Dawes, P. T., Packham, J. C. & Mattey, D. L. Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: A cross-sectional study. Arthritis Res.Ther. 14. https://doi.org/10.1186/ar3804 (2012).
Grainger, D. J. et al. The serum concentration of active transforming growth-factor-beta is severely depressed in advanced atherosclerosis. Nat. Med. 1, 74–79. https://doi.org/10.1038/nm0195-74 (1995).
Pardali, E., Goumans, M. J. & ten Dijke, P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 20, 556–567. https://doi.org/10.1016/j.tcb.2010.06.006 (2010).
Clegg, C. H. et al. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int. Immunol. 9, 1111–1122. https://doi.org/10.1093/intimm/9.8.1111 (1997).
Dai, Y., Masterman, T., Huang, W. & Hillert, J. Analysis of a CD40 ligand dinucleotide microsatellite in multiple sclerosis. Eur. J. Immunogenet. 29, 81–85. https://doi.org/10.1046/j.1365-2370.2002.00270.x (2002).
Martin-Donaire, T. et al. Association of the microsatellite in the 3 ' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: A case-control study. Arthritis Res. Ther. 9. https://doi.org/10.1186/ar2288 (2007).
Citores, M. J. et al. The dinucleotide repeat polymorphism in the 3 ’ UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus. Ann. Rheum. Dis. 63, 310–317. https://doi.org/10.1136/ard.2003.006148 (2004).
Acknowledgements
Thanks to Bin Zhao (Official Wechat Account: SCIPhD) of ShengXinZhuShou for English editing on the manuscript.
Author information
Authors and Affiliations
Contributions
Y.S. and Z.J. conceived and designed this study. Y.S. wrote this manuscript. L.J. and J.X. revised this manuscript. Y.S. made these figures with the help of Z.J.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shi, Y., Jiang, Z., Jiang, L. et al. Integrative analysis of key candidate genes and signaling pathways in acute coronary syndrome related to obstructive sleep apnea by bioinformatics. Sci Rep 11, 14153 (2021). https://doi.org/10.1038/s41598-021-93789-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-93789-2
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.